NCT06181019View on ClinicalTrials.gov

Acupuncture Combined With Mirabegron in the Treatment of OAB

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2024

Conditions
Overactive Bladder
Interventions
DRUG

50 mg of mirabegron

Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.

COMBINATION_PRODUCT

acupuncture combined with mirabegron.

Patients in the treatment group were treated with acupuncture combined with mirabegron.

Trial Locations (1)

341000

Ganzhou People's Hospital, Ganzhou

All Listed Sponsors
lead

The Affiliated Ganzhou Hospital of Nanchang University

OTHER